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Abstract
Background: p27(Kip1) is a cyclin-dependent kinase inhibitor. When up-regulated, p27 inhibits G1-to-S
phase transition of the cell cycle. This report addresses the question of whether various nutritional and
chemopreventive anti-cancer agents up-regulate the expression of p27 in preneoplastic and neoplastic
cells.
Results: Experimental evidence presented in the first half of this report shows that these agents fairly
faithfully up-regulate expression of p27 in mouse epidermal (JB6) and human breast cancer (MCF7, MDA-
MB-321, and AU565) cells. Up-regulation appears to be specific to p27 because expression of cyclin D1,
E, and A, and p21Cip1/Waf1 was not modulated by these agents. Up-regulation of the expression of p27
is likely due to the activation of translation rather than transcription of p27 because (a) up-regulation is
mediated by the 5'-untranslated region (-575) of the p27 gene and (b) the antibiotic actinomycin D, an
inhibitor of transcription, did not attenuate the up-regulation of p27. This latter finding is likely to preclude
the existence of cryptic transcription factor binding site(s) in the 5'-untranslated region of p27 gene. The
experimental evidence, presented in the second half of this report, was obtained using the 5'-untranslated
region (-575) of p27 gene. The evidence suggests that cancer preventive agents up-regulate expression of
p27 by at least four different molecular signaling pathways: (a) Caloric restriction is likely to up-regulate
p27 expression via 5'-AMP-activated protein kinase (AMPK; a metabolic energy sensor or cellular fuel
gauge), tuberous sclerosis complex (TSC), and mammalian target of rapamycin (mTOR). Amino acid
deficiencies also up-regulate the expression of p27 using some components of this pathway. (b) 4-
Hydroxytamoxifen (but not tamoxifen), genistein (but not genistin), daidzein, and probably other
nutritional and chemopreventive anti-cancer agents could up-regulate expression of p27 via receptor
protein tyrosine kinases (RPTKs), phosphoinositide 3-kinase (PI3K), phosphoinosite-dependent kinase
(PDK), Akt/PKB and mTOR. (c) Expression of p27 could also be up-regulated via RPTKs followed by
MAPKs – MEK, ERK and p38MAPK – and probably MNK. Finally, (d) global hypomethylation of 5'-m7G cap
of mRNAs could also up-regulate expression of p27.
Conclusion: Based on these findings, we conclude that various nutritional and chemopreventive anti-
cancer agents up-regulate expression of p27 in (pre)neoplastic cells.
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Background
The cyclin-dependent kinase (CDK) inhibitor p27(Kip1)
is a key cell-cycle regulator of G1-to-S phase transition [1].
Transcriptional and translational control, sequestration in
cyclin D1 complexes and localization all regulate p27 in
G1 phase.
Preliminary studies using either N-methyl-N-nitrosourea
(MNU)-induced rat breast cancer model or human breast
cancer cell lines in vitro had suggested, but not proved,
that nutritional and chemopreventive anti-cancer agents
increase p27 protein expression. This apparent increase in
p27 protein expression might have been due to either
increased synthesis or decreased degradation, or a combi-
nation of both [1].
To address this question, the effects of various nutritional
and chemopreventive anti-cancer agents on the activity of
the proximal 5'-upstream region of p27 gene were investi-
gated by transient transfection assay. This study provided
evidence that the up-regulation of p27 protein expression
is at least in part due to increased synthesis and that this
increase fairly faithfully recapitulates the cancer preven-
tive activity of nutritional and chemopreventive anti-can-
cer agents. Further studies were conducted to gain some
insight into the molecular basis of this increase in the syn-
thesis of p27.
Results
Nutritional and chemopreventive anti-cancer agents up-
regulate the activity of proximal 5'-upstream region (-
1797) of p27 gene in a manner specific to p27
Preliminary studies using in vivo model of MNU-induced
rat mammary cancer and in vitro model of cultured cells
had suggested – but not proved – that various nutritional
and chemopreventive anti-cancer agents, including mod-
erate dietary restriction, up-regulated the expression of
p27 (Fig. 1a).
To prove or disprove this preliminary observation, each
luciferase reporter vector containing proximal 5'-
upstream region of the cyclin D1, cyclin A, p27 (p27-Kpn I)
or p21 genes (Fig. 1b) was transiently transfected into pro-
motion-sensitive (P+) JB6 mouse epidermal cells and
then treated with all-trans-retinoic acid (atRA), 9-cis-retin-
oic acid (9cRA), 13-cis-retinoic acid (13cRA), phorbol 12-
myristate 13-acetate (TPA), 1α, 25-dihydroxyvitamin D3
(calcitriol), or dexamethasone. Phorbol 12-myristate 13-
acetate (TPA) is not a chemopreventive anti-cancer agent;
rather it is a tumor promoter. But TPA was included here
to demonstrate that it could stimulate the activity of the
proximal 5'-upstream region (-1745) of cyclin D1. The
TPA, three retinoic acids and dexamethasone exerted spu-
rious effects on the backbone of the empty luciferase
reporters when JB6 cells were used. Therefore, a special
method, as described in the Methods and Materials sec-
tion, was used to correct these effects when JB6 cells were
exposed to these compounds.
The proximal 5'-upstream region (-1745) of cyclin D1 was
activated only by TPA (Fig. 1c). Using a wild-type -963 cyc-
lin D1 and a -963 cyclin D1 mutated at AP-1, it was con-
firmed that TPA activated the proximal 5'-upstream region
(-1745) of cyclin D1 gene primarily through its TPA-
response element (TRE).
The proximal 5'-upstream region of cyclin A and p21 genes
were not activated by any of the compounds tested (Fig.
1d and 1f).
In contrast, the proximal 5'-upstream region (-1797) of
p27 gene (p27-Kpn I) was activated by four nutritional
and chemopreventive anti-cancer agents, namely all-trans-
retinoic acid (atRA), 9-cis-retinoic acid (9cRA), 13-cis-
retinoic acid (13cRA) and dexamethasone (Fig. 1e).
Activation of the proximal 5'-upstream region (-1797) of 
p27 gene fairly faithfully recapitulates breast cancer 
preventive activity of various nutritional and 
chemopreventive anti-cancer agents
To investigate whether this specific activation of the prox-
imal 5'-upstream region (-1797) of p27 gene (p27-Kpn I)
recapitulates breast cancer preventive activity of various
nutritional and chemopreventive anti-cancer agents, -
1797 p27 (p27-Kpn I) was transfected into three different
human breast cancer cell lines – estrogen receptor (ER)-
positive MCF7 (Fig. 2a), ER-negative MDA-MB-231 (Fig.
2b), and ER-negative AU565 (Fig. 2c) – and then exposed
to the following eighteen different compounds for 24
hours: 4-hydroxytamoxifen, tamoxifen, 17β-estradiol, ICI
182 780, genistein, genistin, daidzein, epigallocatechin-3-
gallate, epigallocatechin, resveratrol, curcumin, taxifolin,
mifepristone (RU486), all-trans-retinoic acid (atRA), 9-cis-
retinoic acid (9cRA), 13-cis-retinoic acid (13cRA), 1α, 25-
dihydroxyvitamin D3 (calcitriol), or dexamethasone. Pre-
liminary studies indicated that none of these compounds
exerted any spurious effects on the backbone of the empty
luciferase reporter when human breast cancer cells were
used.
4-Hydroxytamoxifen – but not tamoxifen – is the ultimate
cancer preventive agents. Our results showed that 4-
hydroxytamoxifen – but not tamoxifen – activated -1797
p27 in ER-positive MCF7 (Fig. 2a) and ER-negative MDA-
MB-231 (Fig. 2b). These results indicated that (a) the
activity of -1797 p27 recapitulated the differential breast
cancer preventive efficacy of 4-hydroxytamoxifen and
tamoxifen and that (b) the estrogen receptor (ER) was not
involved in the activation of -1797 p27. In AU565 cells,
both 4-hydroxytamoxifen and tamoxifen activated -1797Cancer Cell International 2006, 6:20 http://www.cancerci.com/content/6/1/20
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Nutritional and chemopreventive anti-cancer agents up-regulate the activity of the proximal 5-upstream region (-1797) of p27  gene in a manner specific to p27 Figure 1
Nutritional and chemopreventive anti-cancer agents up-regulate the activity of the proximal 5-upstream 
region (-1797) of p27 gene in a manner specific to p27. (a) Preliminary studies suggesting – but not proving – that vari-
ous nutritional and chemopreventive anti-cancer agents, including moderate caloric/dietary restriction, up-regulate p27 expres-
sion. (b) Schematic drawing of the proximal 5'-upstream region of the genes used in this experiment: (c) -1745 cyclin D, (d) -
8100 cyclin A, (e) -1797 p27 (p27-Kpn I), and (f) -2320 p21. The JB6 cells, transfected with these proximal 5'-upstream region of 
the genes, were exposed to all-trans-retinoic acid (atRA) (1 μM), 9-cis-retinoic acid (9cRA) (1 μM), 13-cis-retinoic acid (13cRA) 
(1 μM), phorbol 12-myristate 13-acetate (TPA) (16.2 nM), 1α, 25-dihydroxyvitamin D3 (calcitriol) (240 nM), or dexametha-
sone (1 μM) for 24 hours. All assays were performed in triplicates and the transfection of JB6 cells with each 5'-upstream 
region of the genes was repeated three times.
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Activation of the proximal 5'-upstream region (-1797) of p27 gene fairly faithfully recapitulates breast cancer preventive activity  of various nutritional and chemopreventive anti-cancer agents Figure 2
Activation of the proximal 5'-upstream region (-1797) of p27 gene fairly faithfully recapitulates breast cancer 
preventive activity of various nutritional and chemopreventive anti-cancer agents. (a) Estrogen-positive (ER) MCF 
7, (b) ER-negative MDA-MB-231, and (c) ER-negative AU565 cells, transfected with -1797 p27 (p27-Kpn I), was exposed to 4-
hydroxytamoxifen (258 nM), tamoxifen (269 nM), 17β-estradiol (367 nM), ICI 182 780 (165 nM), genistein (370 nM), genistin 
(231 nM), daidzein (393 nM), epigallocatechin-3-gallate (218 nM), epigallocatechin (326 nM), resveratrol (438 nM), curcumin 
(271 nM), taxifolin (329 nM), mifepristone (RU486) (233 nM), all-trans-retinoic acid (atRA) (1 μM), 9-cis-retinoic acid (9cRA) (1 
μM), 13-cis-retinoic acid (13cRA) (1 μM), 1α, 25-dihydroxyvitamin D3 (calcitriol) (240 nM), or dexamethasone (1 μM) for 24 
hours. All assays were performed in triplicates and the transfection experiments were repeated three times.
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p27 (Fig. 2c), suggesting that either tamoxifen was con-
verted to 4-hydroxytamoxifen in these cells or, as the
results presented below suggest, the global rate of tran-
scription was generally reduced in these cells, which, in
turn, activated normally inactive tamoxifen by some
unknown mechanisms.
Similarly, genistein – but not genistin – from soybeans is
the ultimate cancer preventive agents. Our results showed
that genistein – but not genistin – activated -1797 p27 in
MCF7 (Fig. 2a) and MDA-MB-231 cells (Fig. 2b). These
results again indicated that (a) the activity of -1797 p27
recapitulated the differential breast cancer preventive effi-
cacy of genistein and genistin and that (b) the estrogen
receptor (ER) was not involved in the activation of -1797
p27. In AU565 cells (Fig. 2c), however, both genistein and
genistin activated -1797 p27 suggesting again that either
genistin was converted to genistein in AU565 cells or, as
the results presented below suggest, the global rate of tran-
scription was reduced in these cells, which, in turn, acti-
vated normally inactive genistin by some unknown
mechanisms.
Daidzein from soybeans activated -1797 p27 in all three
cell lines (Fig. 2a,b,c).
Epigallocatechin – but not epigallocatechin-3-gallate –
from green tea activated -1797 p27 in MCF7 cells (Fig. 2a),
but neither epigallocatechin nor epigallocatechin-3-gal-
late activated -1797 p27 in MDA-MB-231 cells (Fig. 2b). In
AU565 cells (Fig. 2c), both epigallocatechin and epigallo-
catechin-3-gallate activated -1797 p27. Resveratrol from
grape skin did not activate -1797 p27 in MCF7 cells, but it
did in MDA-MB-231 and AU565 cells. Curcumin from
curry spice and taxifolin from citrus activated -1797 p27 in
MCF7 and AU565 cells, but neither curcumin nor taxifo-
lin activated -1797 p27 in MDA-MB-231 cells.
Of the three different forms of retinoic acid tested, 9-cis-
retinoic acid (9cRA) most strongly activated -1797 p27,
followed by all-trans-retinoic acid (atRA) and 13-cis-retin-
oic acid (13cRA) in all three human breast cancer cell
lines. In JB6 mouse epidermal cells, these retinoic acids
almost equally activated -1797 p27 (Fig. 1e). These results
are compatible with those obtained using in vivo experi-
mental animal models of breast cancer.
Dexamethasone activated -1797 p27 in all three human
breast cancer cell lines (Fig. 2a,b,c).
Mifepristone (RU486) and 1α, 25-dihydroxyvitamin D3
(calcitriol) did not activate -1797 p27 in all three human
breast cancer cell lines (Fig. 2a,b,c).
The estrogen receptor (ER)-negative AU565 cells were
unusual in that sixteen of the eighteen compounds tested
activated -1797 p27 (Fig. 2c); only mifepristone (RU486)
and 1α, 25-dihydroxyvitamin D3 (calcitriol) did not acti-
vate it. This unusually high cancer preventive activity of
nutritional and chemopreventive anti-cancer agents in
AU565 cells might be due to its potentially reduced rate of
transcription.
In summary, with the possible exception of AU565 cells,
(a) activity of -1797 p27 in either estrogen receptor (ER)-
positive or -negative human breast cancer cells fairly faith-
fully recapitulated the breast cancer preventive activity in
vivo of the various nutritional and chemopreventive anti-
cancer agents and (b) the effective doses for the activation
of -1797 p27 by these agents were within the range that
had been found effective for in vivo rat models of breast
cancer.
Deletion analysis indicates that various nutritional and 
chemopreventive anti-cancer agents activate the proximal 
5'-upstream region (-1797) of p27 gene through its 5'-
untranslated region (5'UTR) (-575)
To determine the core element for the activation of the
proximal 5'-upstream region (-1797) of p27 gene, (P+)
JB6 mouse epidermal cells or estrogen receptor (ER)-neg-
ative MDA-MB-231 human breast cancer cells were trans-
fected with the following deletion mutants of -1797 p27
(Fig. 3a) and then treated with various nutritional and
chemopreventive anti-cancer agents: -1797 p27 (p27-Kpn
I) [4], -774 p27 (p27-Apa I) [4], -575 p27 (p27-5'UTR)
[5,6], -435 p27 (p27-MB) [4], and -417 p27 (p27-IRES)
[5,6]. Preliminary studies indicated that TPA, three retin-
oic acids and dexamethasone exerted spurious effects on
the backbone of the empty luciferase reporters when JB6
cells were used. Therefore, special method, as described in
the Methods and Materials section, was used to normalize
these effects in these cases. When human breast cancer
cells were used, none of the agents tested exerted any spu-
rious effects on the backbone of the empty luciferase
reporters.
The results of deletion analysis suggested that, in all cases
without exception (Fig. 3b to 3e), including those not
shown here, the various nutritional and chemopreventive
anti-cancer agents activated proximal 5'-upstream region
(-1797) of p27 gene at least through -575 p27 (5'-untrans-
lated region (5'UTR) of p27  gene). When the regions
shorter than -575 p27 (p27-5'UTR) were tested, the activ-
ities tended to either stay constant or be reduced; the activ-
ities never increased above that of -575 p27 (p27-5'UTR).Cancer Cell International 2006, 6:20 http://www.cancerci.com/content/6/1/20
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Deletion analysis indicates that various nutritional and chemopreventive anti-cancer agents activate the proximal 5'-upstream  region (-1797) of p27 gene through its 5'-untranslated region (5'UTR) Figure 3
Deletion analysis indicates that various nutritional and chemopreventive anti-cancer agents activate the prox-
imal 5'-upstream region (-1797) of p27 gene through its 5'-untranslated region (5'UTR). (a) Deletion mutants of -
1797 p27 (p27-Kip I) used in this experiment: -1797 p27 (p27-Kpn I), -774 p27 (p27-Apa I), -575 p27 (p27-5'UTR), -435 p27 
(p27-MB), and -417 p27 (p27-IRES). The (P+) JB6 mouse epidermal cells and estrogen receptor (ER)-negative MDA-MB-231 
cells were transfected with these deletion mutants and then exposed to (b) 9-cis-retinoic acid (9cRA) (1 μM), (c) dexametha-
sone (1 μM), (d) 4-hydroxytamoxifen (258 nM), or (e) genistein (370 nM) for 24 hours. All assays were performed in triplicates 
and the transfection experiments were repeated three times.
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The -575 p27 (5'-untranslated region (5'UTR) of p27 gene) 
is unlikely to contain any cryptic transcription factor 
binding sites
To investigate if -575 p27 (p27-5'UTR) contains any cryp-
tic transcription factor binding sites, the activity of the
region was stimulated with 4-hydroxytamoxifen in the
presence of an antibiotic actinomycin D. Figure 4a shows
the schematic drawing of the pGL3 control-p27-5'UTR-
luciferase reporter plasmid. This plasmid – pGL3 control
– contains SV40 promoter in its backbone. Preliminary
tests using pGL3 control without p27-5'UTR insert had
demonstrated that 4-hydroxytamoxifen, tamoxifen, or
vehicle (DMSO) did not exert any spurious effects on the
SV40 promoter when human breast cancer cells were
used. The outline of the protocol for actinomycin D exper-
iment is shown in Figure 4b. Actinomycin D was added
one hour before the addition of 4-hydroxytamoxifen,
tamoxifen, or vehicle (DMSO) and then the cells were
kept exposed to both compounds for another 24 hours.
The results (Fig. 4c) indicated that in the absence of actin-
omycin D, only 4-hydroxytamoxifen significantly up-reg-
ulated the activity of -575 p27 (p27-5'UTR) above that of
vehicle (DMSO) in MDA-MB-231 cells; tamoxifen did not
up-regulate it. The addition of actinomycin D in the pres-
ence of vehicle (DMSO) alone decreased the baseline
activity of -575 p27 (p27-5'UTR) by about 53% relative to
the activity observed in the absence of actinomycin D.
Despite this decrease in the baseline activity in the pres-
ence of actinomycin D, 4-hydroxytamoxifen still signifi-
cantly up-regulated the activity of -575 p27 (p27-5'UTR)
above that of vehicle (DMSO). These findings suggested
that transcriptional mechanisms were not involved in the
up-regulation of the activity of -575 p27 (p27-5'UTR) by
4-hydroxytamoxifen, precluding the involvement of any
cryptic transcription binding sites in this region. What was
more surprising was the finding that tamoxifen, which
had previously been inactive in the absence of actinomy-
cin D, significantly up-regulated the activity of -575 p27
(p27-5'UTR) in the presence of actinomycin D, suggesting
that the overall level of global transcriptional rate might
somehow modulate the effects of tamoxifen on the activ-
ity of -575 p27 (p27-5'UTR) in MDA-MB-231 cells.
Inhibition of certain receptor protein tyrosine kinases 
(RPTKs) up-regulates the activity of -575 p27 (5'-
untranslated region (5'UTR) of p27 gene)
The results presented above suggested that the estrogen
receptor was not involved in the activation of -1797 p27
(p27-Kpn I) by 4-hydroxytamoxifen, genistein, daidzein
and probably other nutritional and chemopreventive
anti-cancer agents. Tamoxifen and genistein have been
known to exhibit anti-estrogenic activity, but in addition,
they have been reported to inhibit receptor protein tyro-
sine kinase (RPTK) activity at a slightly higher concentra-
tions [9,10]. Epigallocatechin-3-gallate has also been
reported to block activation of RPTKs such as epidermal
growth factor receptor (EGFR) and HER-2/neu receptor,
which are generally overexpressed or constitutively active
in many human malignancies [11,12].
Although multiple RPTKs are known to be expressed in
human breast cancer cells, synthetic inhibitors of four
RPTKs – epidermal growth factor receptor (EGFR), HER/
ErbB, platelet-derived growth factor receptor (PDGFR)
and insulin receptors (IR and IGF-1R) – were used to
investigate whether they up-regulate the activity of -575
p27 (p27-5'UTR). Preliminary studies had demonstrated
again that none of them exerted any spurious effects on
the backbone of the empty luciferase reporter plasmids in
all four types of cells used in this experiment.
The following four synthetic inhibitors were used to
inhibit EGFR: AG9 (inactive negative control for inhibi-
tion of EGFR), AG18 (broad spectrum protein tyrosine
kinase inhibitor, inhibits EGFR autophosphorylation),
AG1478 (specific inhibitor of EGFR), and PD153035
(specific inhibitor of tyrosine kinase activity of EGFR). Of
the four inhibitors, two of them – AG18 and AG1478 –
up-regulated the activity of -575 p27  (p27-5'UTR) in
MCF7 cells (Fig. 5b). However, none of them up-regu-
lated the activity of -575 p27 (p27-5'UTR) in MDA-MB-
231 (Fig. 5a), AU565 (Fig. 5c), and JB6 cells (Fig. 5d).
AG30, a specific inhibitor of c-ErbB, did not up-regulate
the activity of -575 p27 (p27-5'UTR) in any of the cells
tested (Fig. 5a to 5d).
In contrast, AG1295, a specific inhibitor of PDGFR, up-
regulated the activity of -575 p27 (p27-5'UTR) in all four
types of cells (Fig. 5a to 5d).
Three inhibitors of insulin receptors were investigated
using MDA-MB-231 cells (Fig. 5a). Of the three inhibitors,
two of them – IGF-IR inhibitor PPP and AGL2263 (IR and
IGF-1R inhibitor) – up-regulated the activity of -575 p27
(p27-5'UTR) in MDA-MB-231 cells, but AG1024 (IGF-1
inhibitor) failed to up-regulate it.
Taken together, these results suggested that inhibition of
certain RPTKs on the cell surface could up-regulate the
activity of -575 p27 (p27-5'UTR).
Inhibition of certain mitogen-activated protein kinases 
(MAPKs) up-regulates the activity of -575 p27 (5'-
untranslated region (5'UTR) of p27 gene)
When the cell-surface RPTKs are inhibited, the inhibitory
signal could be transmitted to the interior of the cells in
two ways. The inhibition of mitogen-activated protein
kinases (MAPKs) is one of them. Therefore, inhibitors ofCancer Cell International 2006, 6:20 http://www.cancerci.com/content/6/1/20
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It is unlikely that -575 p27 (5'-untranslated region (5'UTR) of p27 gene) contains any cryptic transcription factor binding sites Figure 4
It is unlikely that -575 p27 (5'-untranslated region (5'UTR) of p27 gene) contains any cryptic transcription fac-
tor binding sites. (a) Schematic drawing (adapted from references [5,6]) of the pGL3-control-p27-5'UTR-luciferase reporter 
plasmid. (b) Summary of the experimental protocol. (c) The ER-negative MDA-MB 231 cells were transfected with -575 p27 
(p27-5'UTR) and then either vehicle or actinomycin D (0.5 μg/ml) [29] was added to the medium. One hour after the addition 
of these compounds, the cells were exposed to vehicle, tamoxifen (1.076 μM) or 4-hydroxytamoxifen (1.032 μM) for 24 hours. 
All assays were performed in triplicates and the transfection experiments were repeated three times.
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Inhibition of certain receptor protein tyrosine kinases (RPTKs) up-regulates the activity of -575 p27 (5'-untranslated region  (5'UTR) of p27 gene) Figure 5
Inhibition of certain receptor protein tyrosine kinases (RPTKs) up-regulates the activity of -575 p27 (5'-
untranslated region (5'UTR) of p27 gene). (a) MDA-MB-231, (b) MCF7, (c) AU565, and (d) JB6 cells were transfected 
with -575 p27 (p27-5'UTR) and then exposed to inhibitors of RPTKs for 24 hours. The following inhibitors were used: AG9 
(2.71 μM), AG18 (2.69 μM), AG1478 (1.58 μM), and PD153035 (1.39 μM) to inhibit epidermal growth factor receptor (EGFR); 
AG30 (2.44 μM) to inhibit c-ErbB; AG1295 (2.13 μM) to inhibit platelet-derived growth factor receptor (PDGFR); IGF-1R 
inhibitor PPP (1.21 μM), AG1024 (1.64 μM), and AGL2263 (1.55 μM) to inhibit insulin receptors (IR) and type 1 insulin-like 
growth factor receptors (IGF-1R). All assays were performed in triplicates and the transfection experiments were repeated 
three times.
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MAPKs were used to investigate whether any one or more
of them could up-regulate the activity of -575 p27 (p27-
5'UTR). Again, none of them exerted any spurious effects
on the backbone of the empty luciferase reporter plasmids
in all four types of cells used in this experiment.
PD98059, an inhibitor of MEK, up-regulated the activity
of -575 p27 (p27-5'UTR) in all four types of cells tested
(Fig. 6a). The effects of other inhibitors of MAPKs were
investigated using MDA-MB-231 cells (Fig. 6b). Of the
two inhibitors of ERK tested, ERK activation inhibitor
peptide I up-regulated the activity of -575 p27  (p27-
5'UTR) in MDA-MB-231 cells, but ERK activation inhibi-
tor peptide II did not up-regulate it. And of the four
p38MAPK inhibitors, only SB202190 strongly up-regu-
lated the activity of -575 p27 (p27-5'UTR); the other three
inhibitors – PD169316, SB203580 and SB202474, an
inactive negative control for p38MAPK inhibitors – failed
to up-regulate it. Anisomycin, which activates MAPKs and
stress-activated protein kinases (SAPKs), also slightly up-
regulated the activity of -575 p27 (p27-5'UTR), and the
other two inhibitors – Ro-32-0432 (protein kinase C
(PKC) inhibitor) and hypericin (PKC/ERK inhibitor) –
did not have any significant effects on the activity of -575
p27 (p27-5'UTR).
Inhibition of phosphoinositide 3-kinase/Akt/mammalian 
target of rapamycin (PI3K/Akt/mTOR) also up-regulates 
the activity of -575 p27 (5'-untranslated region (5'UTR) of 
p27 gene)
The signal that the cell-surface RPTKs are inhibited is also
transmitted to the interior of the cells by phosphoi-
nositide 3-kinase/Akt/mammalian target of rapamycin
(PI3K/Akt/mTOR) pathway. Therefore, inhibitors of these
three protein kinases were used next to investigate
whether they also up-regulate the activity of -575 p27
(p27-5'UTR) in MDA-MB-231 cells. Again, preliminary
experiments had been conducted to verify that none of
them had exerted any spurious effects on the backbone of
the empty luciferase reporter plasmids in MDA-MB-231
cells.
The results indicated that LY294,002 (an inhibitor of
PI3K) [5], triciribine (Akt inhibitor) and rapamycin
(mTOR inhibitor) all three of them up-regulated the activ-
ity of -575 p27 (p27-5'UTR) (Fig. 7).
Also shown in Figure 7 are the effects of two cyclooxygen-
ase inhibitors – COX-1 inhibitor FR122047 and COX-2
inhibitor II – both of which failed to up-regulate the activ-
ity of -575 p27 (p27-5'UTR) in MDA-MB-231 cells.
Inhibition of the global methylation of 5'-m7G-cap of 
mRNAs also up-regulates the activity of -575 p27 (5'-
untranslated region (5'UTR) of p27 gene)
There are two ways to suppress the global cap-dependent
translation initiation of 5'-m7G-capped mRNAs, thereby
potentially up-regulating the activity of -575 p27 (p27-
5'UTR) by a set of mechanisms called cap-independent
translation initiation. One way is to inhibit the methyla-
tion of 5'-m7G cap of mRNAs by S-(5'-adenosyl)-L-
methionine (AdoMet or SAM). Another way is to stimu-
late the inhibitory effect of endoplasmic reticulum stress
by increasing the phosphorylation of the eukaryotic trans-
lation initiation factor 2α (eIF2α). The results (Fig. 7)
indicated that NSC 119889, a cell-permeable, competitive
inhibitor of AdoMet (SAM) and which also acts as a global
inhibitor of cap-dependent translation initiation, up-reg-
ulated the activity of -575 p27 (p27-5'UTR) in estrogen
receptor (ER)-negative MDA-MB-231 cells. The salubrinal,
a cell-permeable thiourea compound, that acts as a selec-
tive inhibitor of eukaryotic translation initiation factor 2α
(eIF2α) dephosphorylation by phosphatase complex,
failed to up-regulate the activity of -575 p27 (p27-5'UTR)
in MDA-MB-231 cells (Fig. 7). Again, both inhibitors had
not exerted any spurious effects on the backbone of the
empty luciferase reporter plasmids in MDA-MB-231.
Modulation of the phosphorylation of 5'-AMP-activated 
protein kinase (AMPK; a metabolic energy sensor or 
cellular fuel gauge) either up-regulates or down-regulates 
the activity of -575 p27 (p27-5'UTR)
5'-AMP-activated protein kinase, known as AMPK, acts as
a metabolic energy sensor or cellular fuel gauge playing a
key role in the regulation of energy metabolism [13]. A
number of physiological and pathophysiological stimuli,
including caloric restriction, lead to an increase in the
AMP: ATP ratio within the cell, which activates AMPK by
phosphorylating it at Thr172 in the activation loop. When
activated, AMPK modulates tuberous sclerosis complex
(TSC), down-regulates phosphorylation of mammalian
target of rapamycin (mTOR), eukaryotic translation initi-
ation 4E binding protein 1 (4EBP1) and p70 S6 kinase
(S6K) [13,14,30]. Thus, caloric restriction – by way of
AMPK, TSC, mTOR, and 4EBP1 – might potentially up-
regulate the activity of -575 p27 (p27-5'UTR).
The Figure 8 shows the effects of various modulators of
AMPK phosphorylation on the activity of -575 p27 (p27-
5'UTR) in MDA-MB-231 cells. Again, none of the com-
pounds tested had exerted any spurious effects on the
backbone of the empty luciferase reporter plasmids in
MDA-MB-231 cells. The results indicated that two com-
pounds – rotenone (an inhibitor of mitochondrial elec-
tron transport) and AICA riboside (an analogue of 5'-
AMP) – that are known to increase phosphorylation of
AMPK up-regulated the activity of -575 p27 (p27-5'UTR)Cancer Cell International 2006, 6:20 http://www.cancerci.com/content/6/1/20
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Inhibition of certain mitogen-activated protein kinases (MAPKs) up-regulates the activity of -575 p27 (5'-untranslated region  (5'UTR) of p27 gene) Figure 6
Inhibition of certain mitogen-activated protein kinases (MAPKs) up-regulates the activity of -575 p27 (5'-
untranslated region (5'UTR) of p27 gene). All four types of cells were transfected with -575 p27 (p27-5'UTR) and then 
exposed to the following inhibitors: PD98059 (1.87 μM) to inhibit MEK; ERK activation inhibitor peptide I (0.80 μM) and ERK 
activation inhibitor peptide II (1.42 μM) to inhibit ERK; PD169316 (1.39 μM), SB203580 (1.33 μM), SB202190 (1.51 μM), and 
SB202474 (1.79 μM) to inhibit p38MAPK; anisomycin (1.89 μM) to activate MAPKs and stress-activated proteins kinases 
(SAPKs); Ro-32-0432 (1.02 μM) to inhibit protein kinase C (PKC); and hypericin (0.99 μM) to inhibit PKC/ERK. All assays were 
performed in triplicates and the transfection experiments were repeated three times.
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(also see a recent report [35]). The results shown in Figure
9 also demonstrated that the removal of D-(+)-glucose
from the cell culture medium up-regulated the activity of
-575 p27 (p27-5'UTR). In contrast, the compounds that
are known to decrease phosphorylation of AMPK – excess
D-(+)-glucose and compound C – down-regulated the
activity of -575 p27 (p27-5'UTR).
Metformin is a widely used drug for treatment of type 2
diabetes with no defined cellular mechanism of action. It
has been suggested recently that metformin could increase
phosphorylation of AMPK [15,38,39]. However, the
results, as shown in Figure 8, indicated that metformin
did not up-regulate the activity of -575 p27 (p27-5'UTR)
in MDA-MB-231 cells.
Amino acid deficiency up-regulates the activity of -575 p27 
(p27-5'UTR)
In addition to caloric restriction and growth factor signals,
tuberous sclerosis complex (TSC) could transmit amino
acid deficiency signals to regulate mTOR activity [13]. We
already demonstrated that rapamycin, an inhibitor of
mTOR phosphorylation, up-regulated the activity of -575
p27 (p27-5'UTR) in MDA-MB-231 cells (see Fig. 7). There-
fore, the effects of amino acid deficiency on the activity of
-575 p27 (p27-5'UTR) were investigated using MDA-MB-
231 cells. Again, none of the amino acid deficiencies
tested had exerted any spurious effects on the backbone of
the empty luciferase reporter plasmids in MDA-MB-231
cells. As shown in Figure 9, removal of L-leucine, L-
methionine, L-cysteine, or combination of L-methionine
and L-cysteine, all up-regulated the activity of -575 p27
(p27-5'UTR) in MDA-MB-231 cells. The findings of L-
methionine deficiency are interesting because L-methio-
nine deficiency could up-regulate the activity of -575 p27
(p27-5'UTR) in two ways: one is to decrease methylation
of 5'-m7G cap of mRNAs and another is to decrease phos-
phorylation of mTOR by TSC.
Discussion
The results of the study presented above indicated that
various nutritional and chemopreventive anti-cancer
agents up-regulate the expression of p27 in mouse epider-
mal (JB6) and human breast cancer (MCF7, MDA-MB-
321, and AU565) cells. Up-regulation of the expression of
p27 – measured by the activity of the proximal 5'-
upstream region (-1797) of p27  gene (p27-Kpn I) –
appears to be specific to p27 because expression of cyclin
D1, E, and A, and p21Cip1/Waf1, another cyclin-depend-
ent kinase inhibitor of G1-to-S phase transition, was not
affected by these agents. Furthermore, up-regulation of
the activity of the proximal 5'-upsteam region (-1797) of
p27 gene (p27-Kpn I) fairly faithfully recapitulated the
breast cancer preventive activity of various nutritional and
chemopreventive anti-cancer agents.
Deletion analysis of the proximal 5'-upstream region (-
1797) of p27 gene (p27-Kpn I) indicated that the activities
were maintained fairly constant – neither increased nor
decreased significantly – when -1797 p27 (p27-Kpn I), -
774  p27  (p27-Apa I) and -575 p27  (p27-5'UTR) were
used. When the fragments shorter than -575 p27 (p27-
5'UTR) were used, the activities were either maintained
constant or decreased. Although transcription of the p27
gene to mRNA is likely to begin at the 5'-upstream end (-
575) of the 5'-untranslated region (5'UTR) of the p27
gene, it has been claimed that there could be some cryptic
transcription factor binding sites within the 5'-untrans-
lated region (5'UTR) of the p27 gene (p27-5'UTR). The
general issue here is whether the up-regulation of the
activity of -575 p27 (p27-5'UTR) is due to transcriptional
or translational mechanism. In the earlier literature of p27
on this issue, there used to be a general consensus that
changes in p27 protein levels do not correlate with
changes in the transcriptional rate of p27 gene. Rather,
Inhibition of phosphoinositide 3-kinase/Akt/mammalian tar- get of rapamycin (PI3K/Akt/mTOR) also up-regulates the  activity of -575 p27 (5'-untranslated region (5'UTR) of p27  gene). Furthermore, inhibition of the global methylation of 5'- m7G-cap of other mRNAs also up-regulates the activity of - 575 p27 (5'-untranslated region (5'UTR) of p27 gene) Figure 7
Inhibition of phosphoinositide 3-kinase/Akt/mamma-
lian target of rapamycin (PI3K/Akt/mTOR) also up-
regulates the activity of -575 p27 (5'-untranslated 
region (5'UTR) of p27 gene). Furthermore, inhibition 
of the global methylation of 5'-m7G-cap of other 
mRNAs also up-regulates the activity of -575 p27 (5'-
untranslated region (5'UTR) of p27 gene). The estro-
gen receptor (ER)-negative MDA-MB-231 cells, transfected 
with -575 p27 (p27-5'UTR), were treated with LY 294002 
(3.25 μM) to inhibit PI3K; triciribine (3.12 μM) to inhibit Akt/
PKB, rapamycin (1.09 μM) to inhibit mTOR; COX-1 inhibitor 
FR122047 (1.09 μM) and COX-2 inhibitor II (1.43 μM) to 
inhibit cyclooxygenases; NSC 119889 (7.70 μM) to competi-
tively inhibit S-adenosylmethionine; or salubrinal (1.04 and 
10.4 μM) to inhibit phosphatase of eukaryotic translation ini-
tiation factor 2α (eIF2α) for 24 hours. All assays were per-
formed in triplicates and the transfection experiments were 
repeated three times.
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p27 expression appears to be regulated either by changes
in the rate of proteasome-mediated degradation and/or
the rate at which p27 mRNA is translated [16-18]. To gain
some insight into this issue, the activity of -575 p27 (p27-
5'UTR) was measured in the presence of both 4-hydrox-
ytamoxifen and the antibiotic actinomycin D, an inhibi-
tor of transcription. The results indicated that
actinomycin D did not attenuate the up-regulation of the
activity of 5'-untranslated region (5'UTR) of p27  gene.
This finding could preclude the presence of cryptic tran-
scription factor binding site(s) in this region and favor the
translational, rather than transcriptional, theory of up-
regulation of p27 gene. The actinomycin D experiment
provided another unexpected finding. Tamoxifen, which,
unlike 4-hydroxytamoxifen, had not up-regulated the
activity of -575 p27 (p27-5'UTR) in the absence of actino-
mycin D, up-regulated it in the presence of actinomycin
D. This finding raised the interesting question of whether
the decreased level of global transcription rate could also
be one of the factors that contribute to the up-regulation
of the activity of -575 p27 (p27-5'UTR). In fact, in one of
the human breast cancer cells (AU565), both 4-hydroxyta-
moxifen and tamoxifen were observed to up-regulate the
activity of -1797 p27 (p27-Kpn I), suggesting that the glo-
bal transcriptional rate could be lower in these cells com-
pared to other human breast cancer cells (MDA-MB-231
and MCF7).
If we assume that the activity of 5'-untranslated region
(5'UTR) of the p27 gene is up-regulated by a translational
mechanism, what could be the molecular basis of this
mechanism? Nearly all nucleus-encoded eukaryotic pro-
teins are translated from their respective mRNAs by a
mechanism involving recognition of the 5'-m7G cap of the
mRNAs by eukaryotic translation initiation factor 4E
(eIF4E). In quiescent cells eIF4E activity is repressed, lead-
ing to a global decline in translational rate. In contrast to
the translation of global mRNAs, translation of p27
mRNA is highest during quiescence, suggesting that it
escapes the general repression of translational initiation.
Amino acid and glucose deficiencies up-regulate the activity  of -575 p27 (p27-5'UTR) Figure 9
Amino acid and glucose deficiencies up-regulate the 
activity of -575 p27 (p27-5'UTR). The MDA-MB-231 cells 
were transfected with -575 p27 (p27-5'UTR) and then main-
tained in 0.2% FBS DMEM for 24 hours. At this point in time, 
the medium was changed to a DMEM Labeling Kit purchased 
from Chemicon International (Temecula, CA, USA). This was 
a deficient basal DMEM supplemented with appropriate com-
ponents to prepare complete DMEM and DMEM without D-
(+)-glucose, L-leucine, L-methionine, L-cysteine, or combina-
tion of L-methionine and L-cysteine. Complete DMEM con-
tained 4.5 g/L D-(+)-glucose, 105 mg/L L-leucine, 30 mg/L L-
methionine, and 48 mg/L L-cysteine. The cells were main-
tained in these complete and deficient DMEMs for 24 hours. 
All assays were performed in triplicates and the transfection 
experiments were repeated three times.
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Modulation of 5'-AMP-activated protein kinase (AMPK; a  metabolic energy sensor or cellular fuel gauge) pathway  either up-regulates or down-regulates the activity of -575  p27 (p27-5'UTR) Figure 8
Modulation of 5'-AMP-activated protein kinase 
(AMPK; a metabolic energy sensor or cellular fuel 
gauge) pathway either up-regulates or down-regu-
lates the activity of -575 p27 (p27-5'UTR). The estro-
gen receptor (ER)-negative MDA-MB-231 cells were 
transfected with -575 p27 (p27-5'UTR) and then exposed to 
D-(+)-glucose (20 mM), rotenone (20 μM), or AICA riboside 
(50 μM), compound C (1.25 μM) or metformin (3.02 μM) for 
24 hours. The basal culture medium (DMEM) contained 1 g/L 
(or 5.55 mM) rather than the usual 4.5 g/L (or 25 mM) of D-
(+)-glucose. All assays were performed in triplicates and the 
transfection experiments were repeated three times.
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It was shown that the 5'-untranslated region (5'UTR) of
the p27 mRNA mediates cap-independent translation ini-
tiation [19] and, within the 5'UTR of p27 mRNA, a U-rich
element (polypyrimidine site in the putative internal
ribosome entry site (IRES)) [5,20] and upstream open
reading frame (uORF) [6] were reported to be necessary
for the cap-independent translation initiation of p27
mRNA.
Assuming that the activity of 5'-untranslated region
(5'UTR) of p27 gene is up-regulated by translational rather
than transcriptional mechanisms, further experiments
were conducted, using -575 p27 (p27-5'UTR) and various
putative inhibitors of signaling pathways, to gain some
insight into the basic mechanisms of how various nutri-
tional and chemopreventive anti-cancer agents could
transmit their signals to activate translation initiation of
p27 mRNA. The results of these experiments suggested
that there are at least four signaling pathways – two of
them shown in Figure 10a and all four of them in Figure
10b – that could potentially transmit the signals to acti-
vate translation initiation of p27 mRNA.
Caloric restriction and amino acid deficiencies are likely to 
transmit signals to activate translation initiation of p27 
mRNA via 5'-AMP-activated protein kinase (AMPK, 
metabolic energy sensor, or cellular fuel gauge), tuberous 
sclerosis complex (TSC), mammalian target of rapamycin 
(mTOR), and eukaryotic translation initiation factor 4E 
binding protein 1 (4EBP1) and p70 S6 kinase (AMPK/TSC/
mTOR/4EBP1 and p70 S6K)
Caloric restriction could up-regulate translation initiation
of p27 mRNA through its 5'-untranslated region (p27-
5'UTR) by sending the signal to endoplasmic reticulum
via AMPK, TSC, mTOR, and 4EBP/S6K. Amino acid defi-
ciencies could also send the signals to endoplasmic retic-
ulum via TSC, mTOR, and 4EBP/S6K. Deficiency of L-
methionine is an interesting case because it could also up-
regulate the cap-independent translation initiation of p27
mRNA by down-regulating global methylation of the 5'-
m7G-cap of other mRNAs.
Caloric restriction has long been known to activate AMPK.
The AMPK system is controlled by the balance between
ATP consumption (e.g., by biosynthesis, cell growth, or
muscle contraction) and ATP production via catabolism
[21,22]. If the rate of ATP consumption exceeds its rate of
production, such as during caloric restriction, ADP will
tend to rise and be converted to AMP by the enzyme ade-
nylate kinase. The rise in level of the activating ligand
AMP, coupled with the fall in level of the inhibitory nucle-
otide ATP, activates AMPK, which then switches off ATP-
consuming processes and switches on catabolism in an
attempt to redress the balance.
AMPK, when activated, phosphorylates tuberous sclerosis
complex 2 (TSC2), thereby inhibiting mTOR activation
[13]. In addition to changes in the intracellular AMP/ATP
ratio, the TSC1 (hamartin)-TSC2 (tuberin) complexes
might mediate amino acid signals to regulate mTOR activ-
ity [13].
In mammalian cells, mTOR generally regulates transla-
tion. Eukaryotic translation initiation factor 4E (eIF4E)
binding protein 1 (4EBP1) [30] and ribosomal p70 S6
kinase (S6K), the most extensively studied substrates of
mTOR, are key regulators of protein translation [13].
4EBP1 acts as a translational repressor by binding and
inhibiting the eIF4E, which recognizes the 5'-end m7G cap
of eukaryotic mRNAs. Phosphorylation of 4EBP1 by
mTOR results in a dissociation of 4EBP1 from eIF4E,
thereby relieving the inhibition of 4EBP1 on eIF4E-
dependent (cap-dependent) translation initiation [30].
The inhibition of mTOR, therefore, results in decreased
global cap-dependent translation initiation of 5'-m7G-
capped mRNA, but it could also increase cap-independent
translation initiation of p27 mRNA through its 5'UTR.
Nutritional and chemopreventive anti-cancer agents could 
also up-regulate translation of p27 by transmitting 
inhibitory signals to receptor protein kinases (RPTKs) 
followed by (a) phosphoinositide 3-kinase/Akt/mammalian 
target of rapamycin (PI3K/Akt/mTOR) signaling pathway, 
(b) MAPK/MNK signaling pathway or (c) a combination of 
both
Following growth factor activation of RPTKs, phosphoi-
nositide 3-kinase (PI3K) is recruited to the receptor and
activated resulting in the production of phosphatidyli-
nositol-3,4,5-trisphosphate (PIP3) [23]. This recruits Akt/
PKB to the membrane where it is phosphorylated by
phosphoinositide-dependent kinase 1 (PDK1). Akt/PKB
is then released from the membrane and translocate to
other subcellular compartments.
Akt/PKB is involved in mTOR activation by phosphorylat-
ing mTOR at Ser2448 [13,24]. It is not yet settled whether
Akt/PKB activates mTOR directly or indirectly, but recent
biochemical studies indicated that Akt/PKB directly phos-
phorylates TSC2 and inhibits its function [13]. TSC2 inac-
tivation by Akt/PKB may also inhibit mTOR indirectly
through inhibition of the small GTPase, Rheb [13].
The inhibition of RPTKs, therefore, leads to reduction of
the phosphorylation of mTOR and 4EBP/S6K, thereby
attenuating the global cap-dependent translation initia-
tion of 5'-m7G-capped mRNAs, but at the same time acti-
vating the cap-independent translation initiation of p27
mRNA through its 5'UTR.Cancer Cell International 2006, 6:20 http://www.cancerci.com/content/6/1/20
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Schematic drawings of the hypothetical signaling pathways that could lead to activation of the unusually long 5'-untranslated  region (-575) of p27 mRNA Figure 10
Schematic drawings of the hypothetical signaling pathways that could lead to activation of the unusually long 
5'-untranslated region (-575) of p27 mRNA. The two signaling pathways shown in (10a) are (i) 5'-AMP-activated protein 
kinase (metabolic energy sensor or cellular fuel gauge)/tuberous sclerosis complex/mammalian target of rapamycin (AMPK/
TSC/mTOR) and (ii) receptor protein tyrosine kinases/phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (RPTKs/
PI3K/Akt/mTOR). The four signaling pathways shown in (10b) are (i) the summary of the two signaling pathways indicated 
above, (ii) receptor protein tyrosine kinases/MAPKs (RPTKs/MAPKs), and (iii) global hypomethylation of the 5'-m7G cap of 
mRNAs.
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The inhibitory signals originating from RPTKs could also
be transmitted to MAPK/MNK signaling pathway. It is
known that the activity of eIF4E is regulated not only by
interaction with 4EBP1 but also phosphorylation by
mitogen-activated protein (MAP) kinase-interacting
kinase (MNK) on Ser209. The phosphorylation of eIF4E
via MNK is mediated by the activation of either the ERK or
p38 pathway [25]. The results presented above indicated
that the inhibition of the MEK (an upstream MAPK of
ERK), ERK or p38MAPK could also decrease the phospho-
rylation of eIF4E, thereby reducing the global cap-depend-
ent translation initiation of 5'-m7G-capped mRNAs, but at
the same time activating the cap-independent translation
initiation of p27 mRNA through its 5'UTR.
Global hypomethylation of the 5'-m7G cap of other 
mRNAs could also transmit signals to activate cap-
independent translation initiation of p27 mRNA through 
its 5'UTR
Nearly all mRNAs are post-transcriptionally modified at
their 5' and 3' ends, by capping and polyadenylation,
respectively [26-28]. The m7G-capping at their 5' end pro-
tects the nascent pre-mRNAs against degradation and fail-
ure to cap or loss of cap leads to rapid breakdown of the
mRNAs. The mRNA cap (guanine-N7) methyltransferase
catalyzes methyl transfer from S-adenosylmethionine
(AdoMet or SAM) to GpppRNA to form m7GpppRNA.
The results presented above indicated that the NSC
119889, a cell-permeable, competitive inhibitor of
AdoMet (SAM), inhibits global cap-dependent translation
initiation of 5'-m7G-capped mRNAs, but it could also
increase cap-independent translation initiation of p27
mRNA through its 5'UTR. This finding suggests that the
epigenetic methylation hypothesis of cancer should be
based not only on DNA methylation but also on mRNA
methylation.
Phosphorylation of the α subunit of eukaryotic transla-
tion initiation factor 2 (eIF2α) is a well-documented
mechanism of down-regulating protein synthesis under a
variety of stress conditions, but at the same time it could
also up-regulate the cap-independent translation initia-
tion of p27 mRNA through its 5'UTR. However, contrary
to this expectation, the results presented above indicated
that salubrinal, a cell-permeable thiourea compound, that
acts as a selective inhibitor of translation initiation factor
2α (eIF2α) dephosphorylation by phosphatase complex,
failed to up-regulate the activity of 5'-untranslated region
of p27 gene.
Cross-talk between 5'-AMP-activated protein kinase 
(AMPK) and receptor protein tyrosine kinase (RPTK) 
pathways
Several recent papers have reported that there is a network
of either synergistic or antagonistic cross-talk between 5'-
AMP-activated protein kinase (AMPK) and receptor pro-
tein tyrosine kinase (RPTK) pathways, e.g. Akt
[31,32,37,40], IGF-1 [33], insulin signaling downstream
of PKB [36], MEK [34], and c-Raf [43]. Additionally, a
cross-talks between AMPK and eukaryotic translation ini-
tiation factor 2α (eIF2α) [41] and between c-Raf-1 and
Akt [42] were reported. These reports, if confirmed, would
suggest that the molecular signaling pathways of how p27
expression might be regulated could be a "tangled web"
[42] to say the least.
Conclusion
Based on the results presented above, we conclude that
various nutritional and chemopreventive anti-cancer
agents up-regulate expression of p27 in preneoplastic and
neoplastic cells, thereby inhibiting G1-to-S phase transi-
tion of these cells. (a) These agents appear to up-regulate
expression of p27 specifically. (b) Up-regulation of p27
fairly faithfully recapitulates cancer preventive activity of
nutritional and chemopreventive anti-cancer agents. (c)
Up-regulation of p27 is likely due to the activation of
translation rather than transcription of p27.
Methods
Reagents
All-trans-retinoic acid (atRA), 9-cis-retinoic acid (9cRA),
13-cis-retinoic acid (13cRA), phorbol 12-myristate 13-ace-
tate (TPA), 1α, 25-dihydroxyvitamin D3 (calcitriol), dex-
amethasone, 4-hydroxytamoxifen, tamoxifen, 17β-
estradiol, genistein, genistin, daidzein, epigallocatechin-
3-gallate, epigallocatechin, resveratrol, curcumin, taxifo-
lin, mifepristone (RU486), actinomycin D, anysomycin,
Ro-32-0432, hypericin, LY 294002, rapamycin, D-(+)-glu-
cose, and rotenone were obtained from Sigma-Aldrich (St.
Louis, MO, USA). ICI 182 780 was purchased from TOC-
RIS (Ellisville, MO, USA). Triciribine, NSC 119889, AG9,
AG18, AG30, AG1024, AG1295, AG1478, AGL2263,
PD98059, PD153035, PD169316, SB202190, SB202474,
SB203580, IGF-1R inhibitor PPP, ERK activation inhibitor
peptide I, ERK activation inhibitor peptide II, COX-1
inhibitor FR122047, COX-2 inhibitor II, salubrinal, com-
pound C, and metformin were obtained from Calbio-
chem/EMD (San Diego, CA, USA). AICA riboside was
purchased from Phoenix Pharmaceuticals, Inc. (Belmont,
CA, USA). Dulbecco's Modified Eagle's Medium (DMEM)
labeling kit was obtained from Chemicon International
(Temecula, CA, USA).Cancer Cell International 2006, 6:20 http://www.cancerci.com/content/6/1/20
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Cell cultures
Promotion-sensitive (P+, clone 41.5a) JB6 mouse epider-
mal cell line was kindly provided by Dr. N. H. Colburn
(National Cancer Institute, Frederick, MD, USA). JB6 cells
were grown in Eagle's Minimum Essential Medium
(MEM) supplemented with 5% heat-inactivated fetal
bovine serum (FBS), 2% L-glutamine, and antibiotics.
Human breast cancer cell lines, MCF7, MDA-MB-231, and
AU565, were obtained from the American Type Culture
Collection (Rockville, MD, USA). MCF7 cells were grown
in Dulbecco's Modified Eagle's Medium (DMEM) con-
taining 4.5 g/L of D-(+)-glucose, supplemented with 10%
heat-inactivated FBS, 100 mg/L recombinant human insu-
lin, 2% L-glutamine, and antibiotics. MDA-MB-231 and
AU565 cells were grown in the same culture medium
without insulin. The incubation was carried out at 37°C
in a 5% CO2 humidified chamber. All cells were subcul-
tured after trypsinization with 0.05% trypsin-0.02%
EDTA solution. The cultures were always maintained
below. The cells were checked periodically for mycoplas-
mal infection by DNA fluorochrome staining.
Plasmids
Luciferase reporter plasmids containing one of the follow-
ing proximal 5'-upstream region of the genes were used to
transfect the cells: -1745 cyclin D1 [2], -963 cyclin D1 [2],
-963 AP-1mut cyclin D1 [2], -8100 cyclin A [3], -1797 p27
(p27-Kpn I) [4], -774 p27 (p27-Apa I) [4], -575 p27 (p27-
5'UTR) [5,6], -435 p27 (p27-MB) [4], -417 p27 (p27-IRES)
[5,6], and -2320 p21 [7]. The control luciferase reporter
plasmids that do not contain these inserts were also pre-
pared to test if nutritional and chemopreventive anti-can-
cer agents were exerting any spurious effects on the
backbone rather than the insert of the luciferase reporter
plasmids. We found that none of the nutritional and che-
mopreventive anti-cancer agents tested did not exert spu-
rious effects on the backbone in the human breast cancer
cells, but TPA, the three retinoic acids and dexamethasone
did stimulate the empty luciferase reporter plasmids in
mouse epidermal JB6 cells. Therefore, a proper transfec-
tion protocols as described below at the end of the section
of Transfection and Luciferase Assay were devised when
JB6 cells were exposed to TPA, the three retinoic acids and
dexamethasone.
Transfection and luciferase assay
Transfections were performed according to a published
protocol [8] using FuGENE 6 from Roche Applied Science
(Indianapolis, IN, USA). In brief, 24 hours before reporter
transfection, the cells were seeded into a 60-mm tissue
culture dish at a density of 1.5 × 105 cells/dish and incu-
bated at 37°C in a 5% CO2 humidified chamber. Reporter
transfection was then carried out with 1 μg of luciferase
reporter plasmid and 0.2 μg of pSV-β-galactosidase inter-
nal control plasmid (Promega, Madison, WI, USA) mixed
with 3 μL of FuGENE 6 solution in 3 mL of FBS-free MEM
or DMEM supplemented with only 2% L-glutamine. A
minimum of 5-hour incubation at 37°C was needed for
transient transfection, followed by 18-hour incubation in
either MEM with 5% FBS or DMEM with 10% FBS for
recovery. The transfected cells were then starved in either
MEM or DMEM with 0.2% FBS for 24 hours. The resulting
cells were treated with various compounds in the same
culture medium as described in the figure legends. After
24 hours, the treated cells were collected and lysed using
Reporter Lysis Buffer (Promega, Madison, WI). The result-
ing cell lysates were assayed for luciferase activity using
Luciferase Assay Kit (Promega, Madison, WI, USA) and
TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA,
USA). β-Galactosidase activity was measured using chlo-
rophenol red-β-D-galactopyranoside (CPRG) (Sigma-
Aldrich, St. Louis, MO, USA) as a substrate.
Each luciferase activity driven by a specific proximal 5'-
upstream region of the genes was normalized to β-galac-
tosidase activity, a control for transfection efficiency.
Since, depending on the cell types (e.g., JB6), certain
nutritional and chemopreventive agents (e.g., the three
retinoic acids and dexamethasone) and a tumor promoter
(e.g., TPA) stimulated the normalized luciferase activity of
empty luciferase reporter vector that do not contain an
insert of the specific proximal 5'-upstream region of the
genes, the following formula was used in these excep-
tional cases to correct for this false increase in the relative
luciferase activity:
Relative luciferase activity (%) = (Experimental luciferase
activity/Control luciferase activity) × 100,
where,
Experimental luciferase activity = {Test compound/
None} {Luciferase reporter vector containing a specific
promoter insert},
Control luciferase activity = {Test compound/None}
{Luciferase reporter vector NOT containing a specific pro-
moter insert}, and
Test compound/None = [Luc(Test)/βGal(Test)]/
[Luc(None)/βGal(None)].
Statistical analysis
An experimental value with statistical significance of P ≤
.05 as compared to control (vehicle alone) by t test is indi-
cated as * on top of the vertical bar.
Abbreviations
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TSC, tuberous sclerosis complex; mTOR, mammalian tar-
get of rapamycin; RPTK, receptor protein tyrosine kinase;
PI3K, phosphoinositide 3-kinase; PDK, phosphoi-
nositide-dependent kinase; PKB, protein kinase B; MAPK,
mitogen-activated protein kinase; MEK, mitogen-acti-
vated protein (MAP) kinase kinase; ERK, ERK MAP kinase;
MNK, MAP kinase interacting kinase; m7G, 7-methylgua-
nosine; CDK, cyclin-dependent kinase; MNU, N-methyl-
N-nitrosourea; AP-1, activator protein-1; TPA, phorbol
12-myristate 13-acetate; TRE, TPA-response element;
atRA, all-trans-retinoic acid; 9cRA, 9-cis-retinoic acid;
13cRA, 13-cis-retinoic acid; N, nucleoside (A, G, U or C);
ER, estrogen-receptor; calcitriol, 1α, 25-dihydroxyvitamin
D3; RU486, mifepristone; 5'UTR, 5'-untranslated region;
IRES, internal ribosome entry site; DMSO, dimethyl sul-
foxide; pGL3, pGL3 luciferase reporter vector; SV40, sim-
ian virus 40; EGFR, epidermal growth factor receptor;
PDGFR, platelet-derived growth factor receptor; IR, insu-
lin receptor; IGR-1R, type 1 insulin-like growth factor
receptor; SAPK, stress-activated protein kinase; PKC, pro-
tein kinase C; COX, cyclooxygenase; AdoMet or SAM, S-
(5'-adenosyl)-L-methionine; eIF2α, eukaryotic translation
initiation factor 2α; 4EBP1, eukaryotic translation initia-
tion factor 4E binding protein 1; S6K, p70 S6 kinase;
AICA, 5-amino-4-imidazolecarboxamide; Glc, D-(+)-glu-
cose; Met, L-methionine; Cys, L-cysteine; Leu, L-leucine;
eIF4E, eukaryotic translation initiation factor 4E; uORF,
5'-upstream open reading frame; PIP3, phosphatidylinosi-
tol-3,4,5-triphosphate; MEM, Eagle's minimum essential
medium; FBS, fetal bovine serum; DMEM, Dulbecco's
modified Eagle's medium; EDTA, ethylenediamine-
tetraacetic acid; CPRG, chlorophenol red-β-D-galacto-
pyranoside; βGal, β-galactosidase; Luc, firefly luciferase.
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